VNRX — VolitionRX Income Statement
0.000.00%
Last trade - 00:00- $26.07m
- $33.41m
- $1.73m
Annual income statement for VolitionRX, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.09 | 0.306 | 0.775 | 1.23 | 1.73 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 28.4 | 32.1 | 36.8 | 28.3 | 23.5 |
| Operating Profit | -28.3 | -31.8 | -36 | -27 | -21.7 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -27 | -30.6 | -35.7 | -27.3 | -23.5 |
| Net Income After Taxes | -27 | -30.6 | -35.7 | -27.3 | -23.5 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -26.8 | -30.3 | -35.3 | -27 | -23.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -26.8 | -30.3 | -35.3 | -27 | -23.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -10.2 | -10.9 | -9.91 | -6.23 | -4.37 |